A topical treatment for genital papillomavirus infections

生殖器乳头瘤病毒感染的局部治疗

• 批准号: 7286845
• 负责人: Richard Schlegel
• 金额: $ 17.99万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-15 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7286845
• 关键词: Accounting; Address; Age; Anatomic Sites; Animal Model; Animals; Apoptosis; Applications Grants; Artemisia annua; Artemisinins; Binding; Biological Assay; Canis familiaris; Carrageenan; Cells; Cervical; Cervical cancer vaccine; Characteristics; Chinese Herbs; Clinical; Clinical Trials; Consultations; Coupling; Cryosurgery; DNA; Data; Developed Countries; Developing Countries; Diagnostic; Drug Formulations; Environment; Epithelium; Excision; Female; Generic Drugs; Genital system; Goals; HIV; HIV Infections; HIV Seropositivity; High Prevalence; Human; Human Papilloma Virus Vaccine; Human Papillomavirus; Human papilloma virus infection; Human papillomavirus 16; Human papillomavirus 18; Immunosuppression; In Vitro; Individual; Infection; Infection prevention; Inorganic Sulfates; Laboratories; Lesion; Licensing; Link; Loop electrosurgical excision procedure; Low-Level Laser Therapy; Malignant neoplasm of cervix uteri; Manuscripts; Methods; Modeling; Molecular; Monitor; Mucous Membrane; Operative Surgical Procedures; Oral; Oral cavity; Oral mucous membrane structure; Outcome; Papillomavirus; Papillomavirus Infections; Phase; Poison; Polysaccharides; Population; Prednisone; Prevention; Procedures; Process; Publishing; Recurrence; Research Personnel; Retinal Cone; Sexually Transmitted Diseases; Site; Techniques; Technology; Testing; Therapeutic; Therapeutic immunosuppression; Topical application; Unspecified or Sulfate Ion Sulfates; Vaccines; Vagina; Viral; Virus Diseases; Withholding Treatment; Woman; Work; artemisinine; cost; food preparation; immunosuppressed; improved; in vivo; inhibitor/antagonist; neoplastic; oral wart; prevent; programs; prophylactic; tumor

DESCRIPTION (provided by applicant): HIV-positive individuals have a higher prevalence of HPV infection and its pre-neoplastic sequelae than age-adjusted populations. While prophylactic vaccines will soon be available commercially for the prevention of HPV infection and cervical cancer, these vaccines will have little or no benefit for HIV-positive women who are already HPV-infected. In addition, theses vaccines do not prevent infection with several HPV types that account for 20-30% of cervical cancers. Therapeutic and preventative strategies to combat these HPV lesions are desperately needed. In this application, we will examine two compounds which show dramatic potential for preventing and treating this sexually transmitted disease. The first compound is carrageenan, which was recently shown by Dr. John Schiller's laboratory to be a potent inhibitor of papillomavirus infection in vitro by blocking cellular attachment. This is a non-toxic compound used in food preparations and, in consultation with Dr. Schiller, we will evaluate carrageenan's ability to inhibit vaginal papillomavirus infections. The second compound is dihydroartemisinin (derived from the Chinese herb, Artemisia annua). Dihydroartemisinin strongly induces apoptosis in HPV-expressing cervical cells and prevents tumor formation in vivo (using a canine oral papillomavirus model). In this application we propose to develop the first in vivo assay for papillomavirus infection of the female genital tract. Our first two years (the R21 phase) will focus on adapting the canine oral papillomavirus (COPV), which normally infects the oral mucosa, to infect and induce tumors in vaginal mucosa. In humans, the oral and genital mucosae are infected by the same HPV types. In the dog, COPV prefers the oral mucosa but it can also spread to the genital tract if the animals are mildly immunosuppressed. We plan to use documented methods of immunosuppression to develop a simple and reproducible assay for papillomavirus infection of vaginal epithelium. In the R33 phase of the application, we will formulate dihydroartemisinin derivatives and carrageenan and test them for their ability to inhibit papillomavirus infection, replication and tumor formation. We will also determine if viral persistence and latency are altered by these compounds. The combined use of this new animal model along with the newly identified inhibitors of papillomvirus infection offer exciting possibilities for extending these trials into humans.

描述（由申请人提供）：hiv阳性个体的HPV感染及其肿瘤前后遗症的患病率高于年龄调整人群。虽然预防HPV感染和子宫颈癌的预防性疫苗很快就会上市，但这些疫苗对已经感染HPV的艾滋病毒阳性妇女几乎没有好处。此外，这些疫苗不能预防几种HPV类型的感染，这些类型占宫颈癌的20-30%。迫切需要治疗和预防策略来对抗这些HPV病变。在这个应用程序中，我们将研究两种化合物，它们显示出预防和治疗这种性传播疾病的巨大潜力。第一种化合物是卡拉胶，最近由约翰·席勒博士的实验室证明，通过阻断细胞附着，它是一种有效的体外乳头瘤病毒感染抑制剂。这是一种用于食品制剂的无毒化合物，在与席勒医生协商后，我们将评估卡拉胶抑制阴道乳头状瘤病毒感染的能力。第二种化合物是双氢青蒿素（从中草药黄花蒿中提取）。双氢青蒿素强烈诱导表达hpv的宫颈细胞凋亡，并在体内阻止肿瘤形成（使用犬口腔乳头瘤病毒模型）。在这个应用程序中，我们建议开发第一个体内检测乳头状瘤病毒感染的女性生殖道。我们的前两年（R21期）将重点研究如何使通常感染口腔黏膜的犬口腔乳头瘤病毒（COPV）感染并诱导阴道粘膜肿瘤。在人类中，口腔和生殖器粘膜被相同类型的HPV感染。在狗身上，COPV倾向于口腔黏膜，但如果动物有轻微的免疫抑制，它也可以传播到生殖道。我们计划使用文献记载的免疫抑制方法来开发一种简单、可重复的阴道上皮乳头瘤病毒感染检测方法。在申请的R33阶段，我们将配制双氢青蒿素衍生物和卡拉胶，并测试它们抑制乳头瘤病毒感染、复制和肿瘤形成的能力。我们还将确定这些化合物是否会改变病毒的持久性和潜伏期。这种新的动物模型与新发现的乳头状病毒感染抑制剂的结合使用为将这些试验扩展到人类提供了令人兴奋的可能性。